[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"genital-psoriasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:genital-psoriasis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100518339","a-study-of-tildrakizumab-in-the-treatment-of-genital-psoriasis-czatch-genital-pso-100518339",false,"NCT06029257","A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)","Effectiveness and Safety of Tildrakizumab in the Treatment of Genital Psoriasis in Austria, Switzerland, and the Czech Republic","Inclusion Criteria:\n\n* Confirmed diagnosis of psoriasis, with significant involvement of genital regions, i.e., sPGA-G greater than or equal to (\\>=) 3.\n* Need for systemic biologic therapy based on the local country specific regulations. Tildrakizumab, in accordance with the SmPC, must be the anti-IL23p19 selected therapy before including the patient in the study.\n* Age 18 - 99 years.\n* Informed consent in writing in accordance with applicable country regulations\n* Patient must have plaque psoriasis affecting a body surface area (BSA) \\>= 1% in a non-genital area at baseline.\n* Patient willing and able to fill out study questionnaires.\n\nExclusion Criteria:\n\n* Patient appears to be unwilling or unable to comply with the requirements of the study or who, in the opinion of the investigator, should not participate in the study.\n* Patient exposed to any experimental treatment in the past 3 months prior to baseline.\n* Any condition preventing prescription of Tildrakizumab according to the SmPC, including but not restricted to any contraindication or history of hypersensitivity or intolerance.\n* Patient dependent on the investigator, including but not restricted to employees of the study site.\n* Previous treatment with Tildrakizumab.","ALL","18 Years","99 Years",{"count":20,"type":21},110,"ESTIMATED","OBSERVATIONAL","The main aim of this study is to check the safety and effectiveness of tildrakizumab regarding the alleviation of symptoms in the genital area after administration according to the summary of product characteristics (SmPC) and to access overall treatment safety and quality of life assessed on multiple scales.",[25],"Genital Psoriasis",[27,28,29,30],"Psoriasis","Plaque psoriasis","Skin Diseases","Tildrakizumab","RECRUITING","2025-01-28",{"date":34,"type":35},"2025-01-29","ACTUAL",{"date":37,"type":35},"2023-11-14",{"date":39,"type":21},"2026-03",{"name":41,"class":42},"Almirall, S.A.","INDUSTRY",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":53,"conditions":54,"keywords":60,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":43},"100577788","real-world-study-of-xeligekimab-for-moderate-to-severe-plaque-psoriasisxp-real-100577788","NCT06802848","Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)","Effectiveness and Safety of Xeligekimab in Adult Patients With Moderate to Severe Plaque Psoriasis: A Multicenter, Prospective, Real-World Study","Inclusion Criteria:\n\nPatients who meet all the following criteria will be included in this study:\n\n1. Patients 18 years of age or older;\n2. Patients with a confirmed clinical diagnosis of moderate to severe plaque psoriasis at the time of screening;\n3. Patients who are deemed suitable for xeligekimab therapy by a clinician and are anticipated to receive xeligekimab treatment for the first time;\n4. Patients who are willing to sign the informed consent form.\n\nExclusion Criteria:\n\nPatients who meet any of the following exclusion criteria will be excluded from this study:\n\n1. Patients with drug-induced psoriasis (such as new-onset or exacerbated psoriasis caused by β-blockers, calcium channel blockers, or lithium);\n2. Patients with hypersensitivity to the active ingredient or any excipient in xeligekimab injection solution;\n3. Patients with other contraindications specified in the prescribing information;\n4. Patients concurrently participating in other clinical studies;\n5. Patients under other conditions or circumstances that investigators do not consider appropriate to include.",{"count":52,"type":21},1000,"Xeligekimab Injection was approved in China on August 20, 2024, for treating adults with moderate to severe plaque psoriasis who are candidates for systemic treatment or phototherapy. Despite the promising efficacy and safety shown in the phase III clinical trial, real-world data is needed to further support clinical decisions for this patient group. This study aims to evaluate the effectiveness and safety of xeligekimab in real-world clinical settings for adults with moderate to severe plaque psoriasis.",[55,56,57,58,59,25],"Plaque Psoriasis","Psoriatic Arthritis","Scalp Psoriasis","Nail Psoriasis","Palmoplantar Psoriasis",[55,56,57,58,59,25,61,62,63,64,65],"Comorbidities of Psoriasis","Xeligekimab","IL-17A","GR1501","Antibodies, Monoclonal","NOT_YET_RECRUITING","2025-01-26",{"date":69,"type":35},"2025-01-31",{"date":71,"type":21},"2025-01-30",{"date":73,"type":21},"2026-12-31",{"name":75,"class":42},"Chongqing Genrix Biopharmaceutical Co., Ltd"]